PSTV Share Price Performance
US$0.68
-0.49 (-41.56%)
92.9% undervalued intrinsic discount
US$9.67
Fair Value
Price US$0.68
AnalystConsensusTarget US$9.67
AnalystLowTarget US$3.00
AnalystHighTarget US$20.50
Fair ValueUS$9.67
Share Pricen/a
Plus Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
PSTV Community Narratives
AN
Fair Value US$9.67 92.9% undervalued intrinsic discount
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$1.63 58.0% undervalued intrinsic discount
Regulatory Hurdles And Funding Risks Will Hamper CNS Pipeline Temporarily
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$20.5 96.7% undervalued intrinsic discount
Advanced Radiotherapeutics Will Capitalize On Aging Cancer Demographics
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Regulatory Hurdles And Funding Risks Will Hamper CNS Pipeline Temporarily
Key Takeaways Heavy dependence on external financing and a narrow pipeline exposes the company to funding risks, shareholder dilution, and vulnerability to clinical or competitive setbacks. Regulatory hurdles, uncertain payer adoption, and pricing pressures threaten timely product commercialization and could constrain future revenue growth and profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$1.63
58.0% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
68.24% p.a.
Profit Margin
16.03%
Future PE
83.96x
Price in 2028
US$1.12
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Key Takeaways Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth. Advancements and strategic partnerships indicate significant market opportunities, enhancing revenue potential and profit margins through reduced costs and expanded markets.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$9.67
92.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
97.03% p.a.
Profit Margin
16.4%
Future PE
302.2x
Price in 2028
US$6.6
Advanced Radiotherapeutics Will Capitalize On Aging Cancer Demographics
Key Takeaways Streamlined operations, non-dilutive funding, and integrated diagnostics position the company for accelerated growth and competitive advantage in underserved CNS oncology markets. Strategic pipeline progress and unique manufacturing capabilities make Plus an attractive acquisition target, with strong potential for outsized long-term gains and market leadership.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$20.5
96.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
93.98% p.a.
Profit Margin
14.17%
Future PE
549.16x
Price in 2028
US$13.85
Trending Discussion
Recently Updated Narratives
AN
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Fair Value: US$1.63 58.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Fair Value: US$9.67 92.9% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Advanced Radiotherapeutics Will Capitalize On Aging Cancer Demographics
Fair Value: US$20.5 96.7% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Plus Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.15
- -45.00%
- -391.33%
- 126.6%
About PSTV
- Founded
- 1996
- Employees
- 21
- CEO
- WebsiteView website
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
